Admit it, you inhaled. It's comments like that that greet David Hill, co-founder and CEO of Cannasat Therapeutics, a Toronto-based company seeking to exploit cannabinoid receptor-targeting drugs including THC (delta-9-tetrahydrocannabinol), the psychoactive component in marijuana (cannabis). However, the laughing ceases once he starts talking about the evidence of the effectiveness of cannabis-derived compounds in treating the symptoms associated with such conditions such as pain, multiple sclerosis, HIV/AIDS, cancer, mood disorders, glaucoma, and many others.

Summarizing the month in European dealmaking.